tbuckley/cabot-search huggingface dataset:
SmartCare at a community cancer center.
Authors: Diane Prager, Joy Muir, Laura M. Miller, Tamera Daily, Deborah Rufus, Kami Doubet, Carrie Jones, Doreen L Link, Laura Hertz, Gloria Riley, Jessica Stewart, Jessica Taylor, C Diane Timm, Kim Tauke, Judith L Williamson
Journal: Journal of Clinical Oncology (2015)

e17535 Background: Cancer and chemotherapy are associated with significant morbidities and toxicities, many of which result in repeated Emergency Department (ED) visits and Hospital admissions. We examined the impact of an aggressive same day triage (SmartCare) on ED use, and symptom management for patients seen over a twelve month period at a Community Cancer Center. Methods: The numbers, diagnoses, and outcomes of all patients seen for SmartCare appointments from December 2013 through December 2014 were reviewed in a blinded manner. Both a telephone triage and walk-in triage system were employed by Oncology RNs to screen patients for potentially life threatening symptoms requiring referral to an ED versus those symptoms which could be efficiently managed as an outpatient by a team of Advanced Practice Nurses with Oncology MD assistance as required. Results: A total of 1876 patients were seen in consultation. Only 2.5% of all patients were immediately referred to an ED for gastrointestinal bleeding, seizures, cardiac chest pain, sepsis and respiratory distress. Of those patients seen in SmartCare , an additional 4% were referred to an ED. Pain was the most common reason for seeking care, totaling 20% of all visits. Side effects from chemotherapy such as nausea, diarrhea and dehydration accounted for 19.1% of all patients seen, with 10.8% of the patients receiving intravenous fluid hydration. Fatigue, swelling , cough and shortness of breath were seen in 17.6% of the patients and could be variably attributed to a combination of factors including the underlying diagnosis, disease progression and chemotherapy. Fever and or infection were present in 12.8% of the patients. Rashes contributed to 4.5% of all encounters. The incidence of pulmonary embolus and deep vein thrombosis was surprisingly low at 1.1%. Patients with anxiety were seen as part of a group of
DSM-III-R and religion
Authors: S G Post
Journal: American Journal of Psychiatry (1990)

Abstract   The interpretation of religion in DSM-III-R contains considerable negative bias and contributes to unfair stereotypes of religious persons. Particularly new religious movements and religious conversion are unfairly interpreted under the DSM-III-R heading, ‘Dissociative Disorder Not Otherwise Specified’. It is suggested that a more balanced and respectful interpretation of religion is needed in DSM-III-R, since psychiatry through its official nomenclature should not contribute to social intolerance of religious nonconformity.
D6-05: Genomic profile of invasion in lung adenocarcinoma with bronchioloalveolar features (AWBF)
Authors: Ming S. Tsao, Sarit Aviel-Ronen, Bradley P. Coe, Lau K. Suzanne, Chang-Qi Zhu, Dan Strumpf, Gilda da Cunha Santos, Igor Jurisica, Wan L. Lam
Journal: Journal of Thoracic Oncology (2007)
Protein-Protein Interaction Analysis in Blood Plasma of Patients with Myelodysplastic Syndromes By Surface Plasmon Resonance Imaging and Mass Spectrometry
Authors: Ondrej Pastva, Kristyna Pimkova, Leona Chrastinova, Marketa Bockova, Jiri Suttnar, Roman Kotlin, Jaromir Novak, Jaroslav Cermak, Jiri Homola, Jan E Dyr
Journal: Blood (2014)
Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
Authors: Atsushi Ohtsu, Josep Tabernero, Yung-Jue Bang, Charles S. Fuchs, Linda Sun, Zhen Wang, Ildiko Csiki, Minori Koshiji, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2016)

TPS4137 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody against PD-1 that prevents binding of PD-1 to PD-L1 and PD-L2 and permits activation of an antitumor immune response. In KEYNOTE-012, pembro showed a manageable safety profile and a 22% ORR in pts with advanced gastric cancer. The randomized, open-label, phase 3 KEYNOTE-061 study (NCT02370498) is designed to compare the efficacy and safety of pembro with those of standard-of-care paclitaxel in the second-line treatment of advanced gastric cancer. Methods: KEYNOTE-061 is designed for patients with metastatic or unresectable gastric or GEJ adenocarcinoma that progressed after first-line treatment with platinum + fluoropyrimidine doublet chemotherapy. Patients with HER2/neu-positive tumors are eligible if they have documented progression on a regimen that also included trastuzumab. Other key eligibility criteria include measurable disease per RECIST v1.1, ECOG PS 0-1, no chemotherapy within 2 wk of first dose of study drug, and provision of a newly obtained or archival tumor sample for assessing PD-L1 status. Eligible pts are randomized 1:1 to receive pembro 200 mg Q3W or paclitaxel 80 mg/m2 IV on days 1, 8, and 15 of each 28-d cycle. Treatment will continue until disease progression, intolerable toxicity, refusal by pt or investigator, or completion of 24 mo of therapy (pembro arm only). Pts in the pembro arm who have a CR after ≥ 24 wk may discontinue after ≥ 2 doses following initial CR. Clinically stable pts who progress per RECIST v1.1 may continue pembro at the discretion of the investigator until a confirmatory CT scan performed ≥ 4 wk later. Response will be assessed every 6 wk per RECIST v1.1 by central imaging vendor review and per RECIST adapted for immunotherapy response patterns. AEs will be assessed throughout treatment and for 30 d thereafter (90 d for serious AEs). Primary efficacy end points are PFS per RECIST v1.1 and OS in pts with PD-L1+ tumors. Secondary end points include PFS and OS in all pts, time to progression, ORR, and duration of response. Enrollment in KEYNOTE-061 is ongoing and will continue until up to 720 pts are enrolled. Clinical trial information: NCT02370498.
Task-Oriented Rehabilitation Program for Stroke
Authors: Heather Tanksley Peters, Stephen J. Page
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic ultrasound-guided drainage of a post-hepatectomy abscess using a lumen-apposing self-expandable metal stent with electrocautery-enhanced delivery system
Authors: Fabia Attili, Shyam Dang, Mihai Rimbaș, Luca Di Maurizio, Giuseppe Ettorre, Adolfo Attili, Alberto Larghi
Journal: Endoscopy (2016)

Endoscopic ultrasound (EUS)-guided drainage of pancreatic fluid collections and of the gallbladder and bile duct after failure of standard procedures is becoming an attractive minimally invasive alternative to percutaneous drainage [1] [2] [3]. These procedures have been facilitated by the development of a specifically designed lumen-apposing self-expandable metal stent (LA-SEMS) and electrocautery-enhanced delivery system (Hot Axios; Boston Scientific Corp., Marlborough, Massachusetts, USA), which allows the procedure to be performed in one step, mostly under EUS guidance without fluoroscopy [4].
Functional and Evolutionary Characterization of a Gene Transfer Agent’s Multilocus “Genome”
Authors: Alexander P. Hynes, Migun Shakya, Ryan G. Mercer, Marc P. Grüll, Luke Bown, Fraser Davidson, Ekaterina Steffen, Heidi Matchem, Mandy E. Peach, Tim Berger, Katherine Grebe, Olga Zhaxybayeva, Andrew S. Lang
Journal: Molecular Biology and Evolution (2016)

Gene transfer agents (GTAs) are phage-like particles that can package and transfer a random piece of the producing cell's genome, but are unable to transfer all the genes required for their own production. As such, GTAs represent an evolutionary conundrum: are they selfish genetic elements propagating through an unknown mechanism, defective viruses, or viral structures "repurposed" by cells for gene exchange, as their name implies? In Rhodobacter capsulatus, production of the R. capsulatus GTA (RcGTA) particles is associated with a cluster of genes resembling a small prophage. Utilizing transcriptomic, genetic and biochemical approaches, we report that the RcGTA "genome" consists of at least 24 genes distributed across five distinct loci. We demonstrate that, of these additional loci, two are involved in cell recognition and binding and one in the production and maturation of RcGTA particles. The five RcGTA "genome" loci are widespread within Rhodobacterales, but not all loci have the same evolutionary histories. Specifically, two of the loci have been subject to frequent, probably virus-mediated, gene transfer events. We argue that it is unlikely that RcGTA is a selfish genetic element. Instead, our findings are compatible with the scenario that RcGTA is a virus-derived element maintained by the producing organism due to a selective advantage of within-population gene exchange. The modularity of the RcGTA "genome" is presumably a result of selection on the host organism to retain GTA functionality.
miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer
Authors: Francesca Orso, Lorena Quirico, Federico Virga, Elisa Penna, Daniela Dettori, Daniela Cimino, Roberto Coppo, Elena Grassi, Angela Rita Elia, Davide Brusa, Silvia Deaglio, Maria Felice Brizzi, Michael B. Stadler, Paolo Provero, Michele Caselle, Daniela Taverna
Journal: Cancer Research (2016)

Abstract miR-214 and miR-148b have been proposed to antagonize the effects of each other in enabling or blocking metastasis, respectively. In this study, we provide evidence deepening their role and interrelationship in the process of metastatic dissemination. Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration. Mechanistic investigations indicated that dual alteration suppressed passage of malignant cells through the blood vessel endothelium by reducing expression of the cell adhesion molecules ITGA5 and ALCAM. Notably, transendothelial migration in vitro and extravasation in vivo impaired by singly alternating miR-214 or miR-148b could be overridden by overexpression of ITGA5 or ALCAM in the same tumor cells. In clinical specimens of primary breast cancer or metastatic melanoma, we found a positive correlation between miR-214 and ITGA5 or ALCAM along with an inverse correlation of miR-214 and miR-148b in the same specimens. Our findings define an antagonistic relationship of miR-214 and miR-148b in determining the dissemination of cancer cells via tumor–endothelial cell interactions, with possible implications for microRNA-mediated therapeutic interventions aimed at blocking cancer extravasation. Cancer Res; 76(17); 5151–62. ©2016 AACR.
Tendances des infections à Chlamydia trachomatis et perspectives de dépistage national au Royaume-Uni
Authors: Jeanne Pimenta, Kevin A. Fenton
Journal: Eurosurveillance (2001)

Une etude pilote a ete menee pour determiner la faisabilite d'un programme de depistage national des chlamydiases genitales au Royaume-Uni. Les resultats preliminaires indiquent un fort taux d'acceptation (70% des candidates) et une bonne couverture de la population ciblee (40% sur une periode de six mois). Plusieurs autres enquetes se poursuivent pour preciser les procedures de depistage et les methodes de notification des partenaires les plus appropries, ainsi que le rapport cout-efficacite d'un programme national.
Arthralgia and Fevers in a Patient With Autoimmune Hepatitis
Authors: Zaid S. Ardalan, Abhinav Vasudevan, Adam G. Testro
Journal: JAMA (2016)

A 66-year-old man taking azathioprene for autoimmune hepatitis presented with a 2-day history of fevers, lethargy, polyarticular arthralgias, and tender erythematous papulonodular lesions on the extensor surfaces of his lower and upper extremities. What would you do next?
Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
Authors: M. Floridia, M.F. Pirillo, A. Degli Antoni, A. Molinari, E. Tamburrini, C. Pinnetti, G. Guaraldi, G. Nardini, G. Masuelli, S. Dalzero, I. Cetin, M. Sansone, R. Amici, M. Ravizza, M. Ravizza, E. Tamburrini, F. Mori, P. Ortolani, E.R. dalle Nogare, F. Di Lorenzo, G. Sterrantino, M. Meli, S. Polemi, J. Nocentini, M. Baldini, G. Montorzi, M. Mazzetti, P. Rogasi, B. Borchi, F. Vichi, B. Del Pin, E. Pinter, E. Anzalone, R. Marocco, C. Mastroianni, V.S. Mercurio, A. Carocci, E. Grilli, A. Maccabruni, M. Zaramella, B. Mariani, G. Natalini Raponi, G. Guaraldi, G. Nardini, C. Stentarelli, B. Beghetto, A.M. Degli Antoni, A. Molinari, M.P. Crisalli, A. Donisi, M. Piepoli, V. Cerri, G. Zuccotti, V. Giacomet, S. Coletto, F. Di Nello, C. Madia, G. Placido, A. Vivarelli, P. Castelli, F. Savalli, V. Portelli, F. Sabbatini, D. Francisci, L. Bernini, P. Grossi, L. Rizzi, S. Alberico, G. Maso, M. Airoud, G. Soppelsa, A. Meloni, M. Dedoni, C. Cuboni, F. Ortu, P. Piano, A. Citernesi, I. Bordoni Vicini, K. Luzi, A. Spinillo, M. Roccio, A. Vimercati, A. Miccolis, A. De Gennaro, B. Guerra, F. Cervi, G. Simonazzi, E. Margarito, M.G. Capretti, C. Marsico, G. Faldella, M. Sansone, P. Martinelli, A. Agangi, A. Capone, G.M. Maruotti, C. Tibaldi, L. Trentini, T. Todros, G. Masuelli, V. Frisina, I. Cetin, T. Brambilla, V. Savasi, C. Personeni, C. Giaquinto, M. Fiscon, E. Rubino, A. Bucceri, R. Matrone, G. Scaravelli, O. Genovese, C. Cafforio, C. Pinnetti, G. Liuzzi, V. Tozzi, P. Massetti, A.M. Casadei, A.F. Cavaliere, M. Cellini, G. Castelli Gattinara, A.M. Marconi, S. Dalzero, V. Sacchi, M. Ierardi, C. Polizzi, A. Mattei, M.F. Pirillo, R. Amici, C.M. Galluzzo, S. Donnini, S. Baroncelli, M. Floridia, P. Villani, M. Cusato, A. Cerioli, M. De Martino, P. Mastroiacovo, F. Parazzini, S. Vella
Journal: Clinical Microbiology and Infection (2016)
Case 40-1982
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely
Journal: New England Journal of Medicine (1982)

A case is described wherein a 29 year old woman was admitted to the hospital because of the possibility of a hepatic tumor; symptoms included abdominal pain, diffuse hepatic enlargement and absence of uptake in an area of the right hepatic lobe. After a normal pregnancy and delivery 11 years earlier the patient used oral contraceptives (OCs) composed of norethindrone with mestranol until 8 years before entry; 5 years before admission she resumed use of an OC containing norethindrone and ethinyl estradiol. She smoked 1.5 packages of cigarettes and drank 1 glass of wine daily, and there was no history of nausea, vomiting, melena, jaundice, dark urine, light stools, hepatitis, or blood transfusions. Benign lesions which are known to be caused by OCs fall into 2 groups: designated focal nodular hyperplasia and liver-cell adenoma. The evidence linking the latter with OCs is more convincing since in case-controlled studies the risk of development of adenomas has been shown to increase with the estrogen strength of the OCs and duration of use; in women who have been taking OCs over 7 years the relative risk is 500 times that for matched control nonusers. The vascular complications of OC therapy include Budd-Chiari syndrome, peliosis hepatis, and periportal sinusoidal dilatation. The patient in this case was diagnosed to have periportal and midzonal hepatic sinusoidal dilatation association with OC medication. She underwent an operation on her liver which proved to be successful combined with cessation of OC use. The mechanism by which OCs cause these lesions is not known. In 5 of 13 cases similar to the one described here clinical and biochemical abnormalities resolved and 1 patient had a follow-up liver biopsy that revealed normal findings 10 months after cessation of OC therapy; there is no evidence to suggest that sinusoidal dilatation is irreversible.
Case 26-1969
Authors: Edward F. Bland, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A forty-five-year-old woman was admitted to the hospital because of painless swelling of the leg.She had been well until four years previously, when there was the sudden onset of loss of consciousness, right hemiplegia, right facial weakness and aphasia. A left carotid arteriographic study was negative. The patient partially regained speech and was able to walk with the aid of a leg brace. Three weeks before admission progressive, painless swelling of the right leg began; she had not walked during the three months before admission.There was no history of a cough, fever, dyspnea, . . .
Haemorrhagic Fever with Renal Syndrome: an analysis of the outbreaks in Belgium, France, Germany, the Netherlands and Luxembourg in 2005
Authors: P Heyman, C Cochez, G Ducoffre, A Mailles, H Zeller, M Abu Sin, J Koch, G van Doornum, M Koopmans, J Mossong, F Schneider
Journal: Eurosurveillance (2007)

This article aims to describe the Haemorrhagic Fever with Renal Syndrome (HFRS) situation in 2005 in five neighbouring countries (Belgium, France, Germany, the Netherlands and Luxembourg) and define the most affected areas. The 2005 HFRS outbreaks in these countries were the most significant in the region since 1990, with a total of 1,114 confirmed cases. The main feature of the epidemic was the extension of the known endemic area in several of the affected countries, with the involvement of urban areas for the first time. A significant increase in the number of cases was noted for the first time in the province of Liège in Belgium and in the Jura department in France.
Tumor-derived circulating endothelial cell clusters in colorectal cancer
Authors: Igor Cima, Say Li Kong, Debarka Sengupta, Iain B. Tan, Wai Min Phyo, Daniel Lee, Min Hu, Ciprian Iliescu, Irina Alexander, Wei Lin Goh, Mehran Rahmani, Nur-Afidah Mohamed Suhaimi, Jess H. Vo, Joyce A. Tai, Joanna H. Tan, Clarinda Chua, Rachel Ten, Wan Jun Lim, Min Hoe Chew, Charlotte A. E. Hauser, Rob M. van Dam, Wei-Yen Lim, Shyam Prabhakar, Bing Lim, Poh Koon Koh, Paul Robson, Jackie Y. Ying, Axel M. Hillmer, Min-Han Tan
Journal: Science Translational Medicine (2016)

A population of cell clusters circulating in cancer patients consist of tumor-derived endothelial cells reflecting features of the tumor vasculature.
Generalization of the effects of unilateral and bilateral ECT
Authors: C M Swartz, G Larson
Journal: American Journal of Psychiatry (1986)

The correlation coefficients among four different measures of seizure duration (motor activity, EEG spikes, EEG total, tachycardia) were substantially lower with unilateral than bilateral ECT. This suggests that unilateral ECT is less well generalized through the brain than bilateral ECT.
Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy
Authors: Yuxin Liu, Luoyuan Li, Quanwei Guo, Lu Wang, Dongdong Liu, Ziwei Wei, Jing Zhou
Journal: Theranostics (2016)

Lanthanide-based contrast agents have attracted increasing attention for their unique properties and potential applications in cancer theranostics.To date, many of these agents have been studied extensively in cells and small animal models.However, performance of these theranostic nanoparticles requires further improvement.In this study, a novel CsLu 2 F 7 :Yb,Er,Tm-based visual therapeutic platform was developed for imaging-guided synergistic cancer therapy.Due to the presence of the heavy alkali metal Cesium (Cs) in host lattice, the nanoplatform can provide a higher resolution X-ray CT imaging than many other reported lanthanide-based CT contrast agents.Furthermore, by using the targeted RGD motif, chemotherapy drug alpha-tocopheryl succinate (α-TOS), and photothermal coupling agent ICG, this nanoplatform simultaneously provides multifunctional imaging and targeted synergistic therapy.To demonstrate the theranostic performance of this novel nanoplatform in vivo, visual diagnosis in the small animal model was realized by UCL/CT imaging which was further integrated with targeted chemo-photothermal synergistic therapy.These results provided evidence for the successful construction of a novel lanthanide-based nanoplatform coupled with multimodal imaging diagnosis and potential application in synergistic cancer theranostics.
Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro
Authors: Sathisha Upparahalli Venkateshaiah, Rakesh Bam, Xin Li, Khan Sharmin, Ling Wen, Randal S. Shelton, Ingrid Teige, Björn Frendéus, Bart Barlogie, Shmuel Yaccoby
Journal: Blood (2013)
Case 28-1964
Authors: Thomas B. Fitzpatrick, Wallace H. Clark
Journal: New England Journal of Medicine (1964)

Presentation of CaseA fifty-seven-year-old woman was admitted to the hospital because of pain in the abdomen.She had been well until five months previously, when she experienced the onset of severe pain in the left upper quadrant of the abdomen, with radiation to the back. An oral cholecystographic study performed at another hospital disclosed a gallstone. She adhered to a diet low in fat, voluntarily reducing her weight from 170 to 145 pounds, but there were four subsequent episodes of abdominal pain radiating to the back, accompanied by nausea and mild vomiting; the attacks subsided in twelve to twenty-four . . .
Transient Smartphone “Blindness”
Authors: Ali Alim-Marvasti, Wei Bi, Omar A Mahroo, John L Barbur, Gordon T Plant
Journal: New England Journal of Medicine (2016)

Two patients presented with loss of vision after viewing a smartphone screen in bed in the dark. The cause appeared to be differential bleaching of photopigment, with one eye becoming light-adapted while the other eye (blocked by a pillow) became dark-adapted.
<i>Notes from the Field</i>: Four Multistate Outbreaks of Human<i>Salmonella</i>Infections Linked to Small Turtle Exposure — United States, 2015
Authors: Kelly Gambino-Shirley, Lauren Stevenson, Katherine Wargo, Laura Burnworth, Jonathan Roberts, Nancy Garrett, Susan Van Duyne, Gillian McAllister, Megin Nichols
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In August 2015, the Food and Drug Administration (FDA) notified CDC of a consumer complaint involving Salmonella Sandiego infection in a child (the index patient), who had acquired a small turtle (shell length <4 inches [<10 cm]) at an Alabama flea market. The subsequent investigation, which included examining data from PulseNet, the national molecular subtyping network for foodborne disease surveillance, identified four multistate Salmonella outbreaks: two involving Salmonella Sandiego and two involving Salmonella Poona. These serotypes have been linked to small turtles in previous outbreaks (1,2). Although selling small turtles as pets in the United States has been banned since 1975 (3), illegal sales still occur at discount stores and flea markets and by street vendors. CDC investigated to determine the extent of the outbreaks and prevent additional infections.